Western Governors University (WGU) NURS5204 D027 Advanced Pathopharmacological Foundations Practice Exam

SSRIs, or selective serotonin reuptake inhibitors, primarily work by inhibiting the reuptake of serotonin in the brain. This means that they block the transporter proteins responsible for taking serotonin back into the presynaptic neuron after it has been released into the synaptic cleft. As a result, there is an increased availability of serotonin in the synaptic space, enhancing its action on postsynaptic receptors. This mechanism is crucial in treating depression, as serotonin is a key neurotransmitter involved in mood regulation. By increasing serotonin levels, SSRIs can help alleviate the symptoms of depression and improve overall mood and emotional stability. The other mechanisms presented do not describe the action of SSRIs. For instance, blocking dopamine receptors refers to a different class of medications used primarily in treating psychosis or schizophrenia, not depression. Increasing norepinephrine levels is characteristic of other antidepressants known as norepinephrine reuptake inhibitors or dual-action antidepressants. Enhancing GABA activity relates to benzodiazepines and other anxiolytic medications rather than SSRIs, which do not primarily influence GABAergic activity in the same way. Thus, the correct understanding of SSRIs focuses on their role in serotonin reuptake inhibition.